JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i11.12968ArticleThe Impact of Early Initiation of Intensive Lipid-Lowering Therapy on the Efficacy and Inflammatory Factors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention https://artdesignp.com/journal/JCNR/9/11/10.26689/jcnr.v9i11.12968KanYue,ZhaoYongfu,GaoHong,ZhaoShihao,LiuJiaxu,ZhangZhanxiu20259112025-12-09Objective: To investigate the impact of early initiation of intensive lipid-lowering therapy on the postoperative efficacy and inflammatory factors in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Methods: A total of 100 ACS patients undergoing PCI admitted to our hospital were selected as the study subjects. They were randomly divided into a control group (treated with statin combined with ezetimibe, n = 41), a study group 1 (initiated with statin combined with PCSK9 inhibitor immediately after surgery, n = 32), and a study group 2 (routinely administered oral statin and initiated with combined PCSK9 inhibitor before discharge, n = 27). The therapeutic efficacy, inflammatory factor levels, and incidence of adverse events were compared and analyzed among the three groups. Results: The therapeutic regimen in study group 1 demonstrated the optimal efficacy and impact on inflammatory factors, followed by study group 2, while the control group showed relatively weaker efficacy, with statistically significant differences (p < 0.05). The overall incidence of adverse reactions was 30.00% in the control group, 5.00% in study group 1, and 10.00% in study group 2, with statistically significant differences among the groups (p < 0.05), with the lowest incidence observed in study group 1. Conclusion: Early intensive lipid-lowering therapy can effectively improve lipid metabolism, suppress inflammatory responses, and reduce cardiovascular events in ACS patients after PCI, suggesting its pleiotropic cardiovascular protective effects.

Li X, Ge Z, Kan J, et al., 2024, Intravascular Ultrasound-Guided Versus Angiography-Guided Percutaneous Coronary Intervention in Acute Coronary Syndromes (IVUS-ACS): A Two-Stage, Multicentre, Randomised Trial. Lancet, 403(10439): 1855–1865.

Faro D, Laudani C, Agnello F, et al., 2023, Complete Percutaneous Coronary Revascularization in Acute Coronary Syndromes with Multivessel Coronary Disease: A Systematic Review. JACC Cardiovasc Interv, 16(19): 2347–2364.

Liao J, Qiu M, Su X, et al., 2024, The Residual Risk of Inflammation and Remnant Cholesterol in Acute Coronary Syndrome Patients on Statin Treatment Undergoing Percutaneous Coronary Intervention. Lipids Health Dis, 23(1): 172.

Wang X, Wei C, Fan W, et al., 2023, Advanced Lung Cancer Inflammation Index for Predicting Prognostic Risk for Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. J Inflamm Res, 16: 3631–3641.

Yuxiu Y, Ma X, Gao F, et al., 2024, Combined Effect of Inflammation and Malnutrition for Long-Term Prognosis in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Cohort Study. BMC Cardiovasc Disord, 24(1): 306.

Özen Y, Özbay M, 2023, Assessment of Systemic Immune-Inflammation Index as an Independent Surrogate Biomarker of No-Reflow Phenomenon in Acute Coronary Syndrome Patients with Coronary Artery Bypass Grafting Undergoing Percutaneous Coronary Intervention of Saphenous Vein Graft. Eur Rev Med Pharmacol Sci, 27(6): 2394–2403.

Liu Y, Wang X, Song G, et al., 2025, Prognostic Effect of Pan-Immune-Inflammation Value Indices in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Clin Appl Thromb Hemost, 31: 1–10.

Handari S, Rohman M, Sargowo D, et al., 2025, Targeting Inflammation with Galectin-3 and PIIINP Modulation Among ST-Segment Elevation Acute Coronary Syndrome Patients Underwent Delayed Percutaneous Coronary Intervention. Biomedicines, 13(2): 259.

Li Y, Liang X, Zhang W, et al., 2021, The Clinical and Angiographic Outcomes of Postdilation After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Interv Cardiol, 2021(1):1–11.

Anayat S, Majid K, Nazir H, et al., 2023, Meta-Analysis on the Efficacy of High-Dose Statin Loading Before Percutaneous Coronary Intervention in Reducing No-Reflow Phenomenon in Acute Coronary Syndrome. Am J Cardiol, 195: 9–16.